17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL
Lower Back Pain
Durham VA Medical CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Lower Back Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Naltrexone Mundipharma Pte Ltd. | Phase 4 | BB |
Buprenorphine Mundipharma Pte Ltd. | Phase 4 | BB |
Oxycodone Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | B |
Adezunap Apurano Pharmaceuticals GmbH | Phase 3 | B |
Tapentadol Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | B |
View all 16 →
Same molecule, other indications
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →